Drug intelligence / Profile preview

relafenopride

Development stage: Unknown
Lead developer: Shandong Provincial Hospital Affiliated to Shandong First Medical University

Overview

Relafenopride α is a therapeutic agent being evaluated in China for the treatment of advanced gastric cancer. According to clinical trial registry information (ChiCTR2600126519), it is currently being studied in a Phase 4 observational, real-world study to assess its safety and effectiveness in adult patients with locally advanced, recurrent, or metastatic gastric cancer. The primary endpoints of these investigations include safety profiles and real-world progression-free survival (rwPFS). The drug is being studied under the sponsorship of Shandong Provincial Hospital.

Brand names: Relafenopride α
Other names: relafenoprideRelafenopride α

Beyond the preview

Go deeper on relafenopride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on relafenopride.

Explore the full profile